1124 Federal Register / Vol. 62, No. 5 / Wednesday, January 8, 1997 / Notices

models based on an adenovirus vector

or other vectors. It is highly desirable

that the collaborator have the resources

to provide new effective vectors for gene

transfer.

2. The modulation of the inducibility

of the heat-sensitive promoter using

appropriate modifications of the

promoter and by using antiinflammatory or other drugs.

3. Dosage and toxicity of local

production of lymphokines applied to

cancer and other diseases.

4. Initial applications in the field of

anticancer therapy, immunomodulatory

gene products and angiogenesis.

The collaborator may also be expected

to contribute financial support under

this CRADA for supplies and personnel

to support these projects.

Dated: December 19, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–335 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

The inventions listed below are

owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

Foreign patent applications are filed on

selected inventions to extend market

coverage for U.S. companies and may

also be available for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

and issued patents listed below may be

obtained by contacting the indicated

licensing specialist at the Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, Maryland 20852–

3804; telephone: 301/496–7057; fax:

301/402–0220. A signed Confidential

Disclosure Agreement will be required

to receive copies of the patent

applications.

Chimeric GAG Pseudovirions

GJ Tobin, MA Gonda (NCI)

OTT Reference No. E–105–96/0 filed 16 May

96

Licensing Contact: Cindy K. Fuchs, J.D., 301/

496–7735 ext 232

This technology is based upon a novel

method for generating pseudovirions

containing HIV Gag and chimeric GagEnv fusion proteins that may be used in

a prophylactic vaccine or to boost the

immune response of HIV-infected

individuals. In addition to the foregoing

method, the invention provides

recombinant chimeric nucleic acids

encoding a Gag-frameshift (fs)-fusion

partner fusion protein; a pseudovirion

comprising a retroviral Gag protein and

a fusion partner; an immunogenic

composition comprising a pseudovirion;

and a Gag-fs-fusion partner fusion

protein. Mice inoculated with the

pseudovirions developed cytotoxic T

lymphocyte responses specific to both

HIV Gag and Env epitopes as well as a

strong humoral response to Gag. The

method allows the packaging of other

non-viral proteins such as interleukins,

interferons, and other cytokines.

(portfolio: Infectious Diseases—

Vaccines, viral, AIDS)

MHC Class II–Restricted Melanoma

Antigens and Their Use in Therapeutic

Methods

SL Topalian, SA Rosenberg, P Robbins (NCI)

Serial No. 08/533,895 filed 26 Sep 95

Licensing Contact: Joseph Contrera, M.S.,

J.D., 301/496–7056 ext 244

The present invention relates to MHC

class II-restricted melanoma antigens

and their use in the treatment of human

cancers. Cytotoxic CD8∂ T cells have

been shown to recognize autologous and

MHC class I compatible allogenic

melanomas expressing shared tumorassociated antigens. Several class Irestricted melanoma-associated antigens

have been identified on a molecular

level. These antigens and derivative

class I-restricted peptides 8 to 10 amino

acids in length are being developed as

clinical vaccines to stimulate CD8∂ T

cell responses against melanoma. While

CD8∂ T cells are important in the

effector phase of the immune response,

the CD4∂ helper arm has been shown to

mediate critical priming and effector

functions as well. T cell receptors on

CD4∂ T cells recognize a complex of

antigenic peptide in conjunction with

MHC class II molecules. Most of these

antigenic peptides are 10–34 amino

acids in length. Strong and lasting

immunity depends, in part, on CD4∂ T

cell function. Therefore, class IIrestricted melanoma antigens may be

useful in immunotherapeutic

approaches to melanoma.

The present invention relates to MHC

class II-restricted melanoma antigens

recognized by CD4∂ T cells and the

nucleic acid sequences that encode

them. The invention contains claims to

MHC class II immunogenic peptides of

tyrosinase and methods of producing an

immune response to these peptides.

This invention also provides a method

for identifying additional class IIrestricted melanoma antigens. (portfolio:

Cancer—Therapeutics, vaccines;

Cancer—Therapeutics,

immunomodulators and

immunostimulants; Cancer—

Therapeutics, biological response

modifiers)

eps15, Substrate for the Epidermal

Growth Factor Receptor Kinase

PP DiFiore, F Fazioli (NCI)

Filed 07 Jun 95

Serial Nos. 08/480,145 and 08/477,389 (both

DIV of 08/095,737, now U.S. Patent

5,487,979)

Licensing Contact: Susan Rucker, J.D., 301/

496–7056 ext 245

These applications describe eps15, a

substrate for the Epidermal Growth

Factor Receptor (EGFR). This substrate

is distinct from a previously identified

substrate for the EGFR known as eps8

(U.S. Patent 5,378,809). EGFR is a cell

surface receptor, with tyrosine kinase

activity, which as been implicated in

mitogenesis via a process known as

mitogenic signal transduction.

Substrates for the EGFR, such as eps15,

may be useful in research on signal

transduction involving EGFR, and as

diagnostic or prognostic indicators due

to their ability to be used in determining

the tyrosine kinase activity of tissue

sample. In particular, recent work with

eps15 fusion proteins has shown that

eps15 may be linked to myeloid

leukemia due to its translocation. Thus,

eps15 may also serve as a tumor marker.

In addition to the cDNA, constructs

expressing eps15, antibodies to eps15,

and methods for assaying eps15

(immunological and DNA based) are

described. (portfolio: Research Tools

and Reagents, receptors and cell lines;

Cancer—Research Reagents)

T-Cell Receptors and Their Use In

Therapeutic and Diagnostic Methods

P Hwu, M Nishimura, SA Rosenberg (NCI)

Serial No. 08/411,098 filed 27 Mar 95

Licensing Contact: Joseph Contrera, M.S.,

J.D., 301/496–7056 ext 244

Tumor infiltrating lymphocytes (TIL)

play an important role in tumor

regression. TIL cells that recognize a

variety of specific tumor antigens have

been identified. This invention

embodies nucleic acid and amino acid

sequences of T-cell receptors which

recognize or bind tumor antigens. The

claims of this invention relate to the use

of these T-cell receptors or

hematopoietic stem cells engineered to

carry these receptors or chimeric

receptors comprised of an antibody

variable region joined to the

cytoplasmic region of CD28 from a Tcell for therapeutic uses. This
Federal Register / Vol. 62, No. 5 / Wednesday, January 8, 1997 / Notices 1125

application addresses technologies

which encompass the broad category of

T-cell receptor and chimeric T-cell

technologies. As such, it is likely that

the technologies will have numerous

applications in the field of

immunotherapy and will potentially be

licensable to multiple applicants for a

variety of novel therapeutic approaches.

(portfolio: Gene-Based Therapies—

Therapeutics, delivery systems;

Cancer—Therapeutics,

immunomodulators and

immunostimulants; Cancer—

Therapeutics, vaccines; Cancer—

Therapeutics, gene therapy, genes)

Process for Producing Monoclonal

Antibodies Reactive With Human

Breast Cancer

J Schlom, D Colcher, M Nuti, PM Hand, FC

Austin (NCI)

Serial No. 06/330,959 filed 15 Dec 81

U.S. Patent No. 4,522,918 issued 11 June 85

Licensing Contact: Joseph Contrera, M.S.,

J.D., 301/496–7056 ext 244

Breast cancer is the second leading

cause of cancer death among women,

having only recently been surpassed by

lung cancer. The incidence rate has

remained somewhat steady, and is

currently about 108 per 100,000. This

invention describes a process to

produce antibodies from hybridoma

cultures for the detection, prognosis,

and treatment of human breast cancer.

These eleven antibodies are activated

only by tumor cells from human

mammary cells and not by apparently

normal human tissues. The isotopes of

ten and the antibodies are IgG of various

subclasses, and one is IgM. The

antibodies may be useful in five major

areas in the management of human

breast cancer: (1) The diagnosis of

primary and metastatic breast tumor

lesions by assay of human body fluids;

(2) the in-situ detection, via gamma

scanning, of primary or metastatic breast

tumor lesions; (3) the treatment of

primary or metastatic breast cancer

using one or a combination of the

antibodies either alone or coupled with

toxic drugs, compounds, or radioactive

isotopes; (4) use of the antibodies in the

staining of populations of human cells

in tissue sections from tumor lesions to

indicate the degree of malignancy of the

cell populations; and (5) the detection of

micro-lesions containing only a few

cells that could not be detected by

conventional staining techniques. A

patent for this invention has been issued

by the U.S. Patent and Trademark

Office. (portfolio: Cancer—Diagnostics,

in vitro, MAb based; Cancer—Research

Materials, MAb based)

Dated: December 23, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–332 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and

Infectious Diseases; Notice of Meeting:

Microbiology and Infectious Diseases

Research Committee

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Microbiology and Infectious

Diseases Research Committee, National

Institute of Allergy and Infectious

Diseases, on February 12–14, 1997 at the

Belmont Conference Center, Manor

House Conference Room, 6555 Belmont

Woods Road, Elkridge, Maryland.

The meeting will be open to the

public from 9 a.m. to 10 a.m. on

February 12, to discuss administrative

details relating to committee business

and for program review. Attendance by

the public will be limited to space

available. In accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and section 10(d) of Public Law 92–463,

the meeting will be closed to the public

for the review, discussion, and

evaluation of individual grant

applications and contract proposals

from 10 a.m. until recess on February

12, from 9 a.m. until recess on February

13, and from 9 a.m. until adjournment

on February 14. These applications,

proposals and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with

the applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Claudia Goad, Committee

Management Officer, National Institute

of Allergy and Infectious Diseases, Solar

Building, Room 3C26, National

Institutes of Health, Bethesda,

Maryland, 301–496–7601, will provide a

summary of the meeting and a roster of

committee members upon request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Ms. Goad in advance of the

meeting.

Dr. Gary Madonna, Scientific Review

Administrator, Microbiology and

Infectious Diseases Research Committee,

NIAID, NIH, Solar Building, Room

4C21, Rockville, Maryland 20892,

telephone 301–496–3528, will provide

substantive program information.

(Catalog of Federal Domestic Assistance

Program No. 93.856, Microbiology and

Infectious Diseases Research, National

Institutes of Health)

Dated: December 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–321 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Child Health and

Human Development; Notice of

Meeting of the National Advisory Child

Health and Human Development

Council

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the National Advisory Child Health and

Human Development Council on

January 27–28, 1997. The meeting will

be held in Building 31, Conference

Room 10, National Institutes of Health,

Bethesda, Maryland. The meeting of the

Subcommittee on Planning will be open

on January 27. The Subcommittee

meeting will be held in Building 31,

Room 2A03, from 8:00 a.m. to 9:30 a.m.

to discuss program plans and the agenda

for the next Council meeting.

Attendance by the public will be limited

to space available.

The Council meeting will be open to

the public on January 27 from 10:00

a.m. until 5:30 p.m. The agenda

includes a report by the Director,

NICHHD, a report by the Mental

Retardation and Developmental

Disabilities Branch, an update on the

Inclusion of Children in Clinical

Research, and other business of the

Council. The meeting will be open on

January 28 upon completion of

applications at approximately 1:00 p.m.

to adjournment if any policy issues are

raised which need further discussion.

In accordance with the provisions set

forth in sections 552b(c)(4), and

552b(c)(6), Title 5, United States Code

and section 10(d) of Public Law 92–463,

the meeting of the full Council will be

closed to the public on January 28 from

8:00 a.m. to approximately 1:00 p.m. for

the review, discussion, and evaluation

of individual grant applications. These

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Ms. Mary Plummer, Executive

Secretary, NACHHD, 6100 Executive